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Introduction: Tumor necrosis factor (TNF) and, possibly, lymphotoxin alpha (LTα) signaling contribute to inflammation
and rheumatoid arthritis (RA) pathogenesis. Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized
monoclonal antibody that blocks and depletes anti-LTα. This phase 2, randomized, head-to-head, active- and
placebo-controlled trial examined the safety and efficacy of pateclizumab compared to adalimumab in RA patients
with an inadequate response to disease-modifying antirheumatic drugs (DMARD-IR).
Methods: Patients (n = 214) with active RA (≥6 swollen and tender joints, C-reactive protein ≥10 mg/L) on oral
DMARDs were randomized (2:2:1) to receive pateclizumab 360 mg, adalimumab 40 mg, or placebo subcutaneously
every 2 weeks. The primary endpoint, 4-variable, 28-joint disease activity score erythrocyte sedimentation rate
(DAS28(4)-ESR) response, was evaluated at 12 weeks using an analysis of covariance (ANCOVA) model with
adjustments for concomitant DMARD use and geographic region. Secondary efficacy endpoints included American
College of Rheumatology (ACR) 20, ACR50, and ACR70 responses at Day 85. Pharmacokinetics, pharmacodynamics,
and immunogenicity of pateclizumab were assessed.
Results: Pateclizumab reduced the DAS28(4)-ESR response (−1.89) at 12 weeks, however, this did not reach
statistical significance compared to placebo (−1.54), while adalimumab (−2.52) differed significantly from both
placebo and pateclizumab. Pateclizumab 12-week ACR20, ACR50 and ACR70 response rates (64%, 33%, and 14%)
suggested clinical activity but were not statistically significant compared to placebo rates (46%, 24%, and 8%,
respectively). CXCL13 serum levels decreased significantly following pateclizumab and adalimumab administration,
demonstrating pharmacological target engagement by both drugs. Overall, adverse events (AEs) were comparable
among all cohorts. Infections were the most common AE, occurring with comparable frequency in all groups.
Serious AEs occurred in 0% of pateclizumab, 5.9% of adalimumab, and 2.3% of placebo patients, with serious
infection in 2.3% of adalimumab patients and none in pateclizumab and placebo patients.
Conclusions: Pateclizumab had a good safety profile in patients inadequately responsive to DMARDs, but no
statistically significant improvement in RA signs and symptoms after 12 weeks of treatment. Adalimumab
demonstrated efficacy and safety comparable to published results in this head-to-head comparison in DMARD-IR
RA patients.
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The risk of disease progression in rheumatoid arthritis
(RA) occurs in patients who do not respond adequately
to available treatment options [1]. Despite the advances
with biological agents for the treatment of RA, there
remains a significant unmet need for those who do not
respond to these agents.
Synovitis in RA develops as a result of infiltration of in-
nate and adaptive immune cells causing a significant in-
flammatory response and cytokine release, including, but
not limited to tumor necrosis factor alpha (TNF-α). During
chronic inflammation these cellular infiltrates organize into
de novo lymphoid aggregates. These ectopic lymphoid ag-
gregates are instigated and maintained by lymphotoxin
(LT)-mediated pathways. Lymphotoxin alpha (LTα) and
beta (LTβ) are two related TNF superfamily (TNFSF)
members produced predominately by activated cells of the
innate and adaptive immune response. LTα exists as a se-
creted homotrimeric molecule (LTα3) that signals via TNF
receptor 1 (TNFR1) and TNFR2 to promote inflammation;
whereas LTα complexed with LTβ (LTα1β2), on the surface
of T and B cells, signals through the LTβ receptor (LTβR)
[2-4]. Lymphoid aggregates in the synovium of RA patients
are associated with LTβ expression, and production of B
cell attractant chemokine CXCL13 [5,6]. B cells in ectopic
lymphoid tissue samples from the lungs of RA patients
with pulmonary complications produce rheumatoid factor
(RF) and autoantibodies to citrullinated proteins [7]. More-
over, the CD4 T helper (Th) subsets Th1 and Th17, which
have been implicated in RA and other autoimmune dis-
eases, express high levels of surface LTα1β2, and depletion
of these cells with a murine anti-LTα-depleting antibody
has demonstrated therapeutic efficacy in preclinical murine
models of RA [4]. In comparison, mice treated with the
LTβR decoy fusion protein, were only afforded efficacy
when treated preventively, consistent with the failure
of LTβR immunoglobulin (LTβR-Ig) to meet clinical end-
points in clinical trials in RA patients [8,9].
Given the role lymphotoxin, TNF-α, and Th cells may
play in inflammation and RA pathogenesis, and the add-
itional role soluble LTα3 may play in disease pathogenesis
[10-15], we generated a fully humanized blocking and
depleting anti-LTα monoclonal antibody (MLTA3698A,
pateclizumab) that blocks LTα3-TNFR interactions, LTα1β2-
LTβR interactions, specifically depletes LTα1β2-expressing
lymphocytes [4]. In a phase I study in patients with active
RA, pateclizumab was well tolerated and provided prelim-
inary evidence of clinical activity [16]. Here, we report on
the ALTARA (Anti-LTa Rheumatoid Arthritis) study - a
phase 2, randomized, head-to-head, active- and placebo-
controlled trial of the safety and efficacy of pateclizumab
compared to adalimumab in RA patients who had an in-
adequate response to disease-modifying antirheumatic
drugs (DMARD-IR).Methods
Study design
The ALTARA study was conducted in 47 centers in 10
countries, including sites in the United States, Europe, and
Latin America. The study was conducted in compliance
with the Declaration of Helsinki and the International
Conference on Harmonization Good Clinical Practice
Guidelines. It was approved by the Comités de Ética
e Investigación en Salud del Centro de Especialidades
Médicas del Sureste S.A. de C.V. (Unidad de Investigacion
Biomedica del Cem). All patients provided written informed
consent before performance of any study procedures.Dose selection
Pateclizumab was administered as subcutaneous (SC)
injections, 360 mg every other week. This study regimen
was selected based on the following considerations:
1) the total exposure was, on average, 60% higher than
the 3 mg/kg biweekly SC doses evaluated in the patec-
lizumab phase I study; 2) this regimen was expected to
result in a maximal pharmacological effect as suggested
by plateaued reductions in serum CXCL13 level in all
dose groups at 1-mg/kg or higher doses; and 3) this regi-
men has 2.2- to 4.5-fold exposure safety coverage by the
highest exposure level assessed in the phase I study [16].
An SC biweekly dose of 360 mg pateclizumab was ex-
pected to maximize the chance of demonstrating clinical
activity while having sufficient safety coverage. Adali-
mumab was administered as 40-mg SC injections every
other week.Entry criteria
Eligible patients were ≥18 years of age, had a diagnosis
of RA for ≥6 months (meeting the American College of
Rheumatology (ACR) 1987 revised criteria for RA [17]),
and had active disease, defined as ≥6 tender/painful
joints (68-joint count) and ≥6 swollen joints (66-joint
count) and a C-reactive protein (CRP) level ≥10 mg/L at
the screening and baseline visits. Additional key in-
clusion criteria included failure of at least one DMARD,
including methotrexate or leflunomide, with current
regimen stable for ≥3 months.
Key exclusion criteria included the following: previous
biologic therapy for RA; evidence of hematopoietic dis-
orders at screening or within 3 months; creatinine >1.5 ×
upper limit of normal (ULN), aspartate aminotrans-
ferase (AST) or alanine aminotransferase (ALT) levels
1.5 × ULN; positive QuantiFeron [18] results for latent
and/or active Mycobacterium tuberculosis; clinically sig-
nificant infection(s); and a history of malignancy, with
the exception of adequately treated nonmetastatic basal
cell or squamous cell cancer of the skin or cervical car-
cinoma in situ.
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This was a phase 2, randomized, double-blind, active-
and placebo-controlled, parallel-group study. Patients
were randomized 2:2:1 to receive one of the following
treatments: pateclizumab 360 mg, adalimumab 40 mg,
or placebo. The study drug was administered SC once
every other week for 10 weeks (baseline (Week 0) and
Weeks 2, 4, 6, 8, and 10). We were unable to construct
a placebo syringe corresponding to the manufactured
syringe supplied with adalimumab. As a result, un-
blinded medical personnel administered the allocated
treatment while maintaining a strict blind for the pa-
tients and medical personnel associated with safety,
joint, and efficacy evaluations.Concomitant medications
Patients continued on a stable background regimen of
RA therapy, which included antimalarial agents, non-
steroidal anti-inflammatory drugs, acetaminophen, and/
or oral corticosteroids (<10 mg prednisone or equiva-
lent/day). Patients continued on either methotrexate or
leflunomide at protocol-defined stable doses through-
out the study. Intra-articular corticosteroids were pro-
hibited in the 6 weeks prior to screening; they were
allowed in one joint during the study, but were discour-
aged between Weeks 10 and 12. For all injected joints,
the treated joint was censored from the efficacy analysis
from the time of injection up to a maximum of 12
weeks.Study assessments
Efficacy measures
The primary objective was to compare the efficacy of
pateclizumab to that of adalimumab by assessing the
change from baseline in the 4-variable, 28-joint disease
activity score erythrocyte sedimentation rate (DAS-ESR
(4)) on Day 85 (Week 12).
Secondary objectives included the durability of the
pateclizumab treatment response, safety of the treat-
ment over 24 weeks, and the efficacy of adalimumab
over 12 weeks. The secondary efficacy endpoints ana-
lyzed throughout the study included the following: the
ACR20, ACR50, and ACR70 response rates, and the
proportions of patients achieving disease remission,
according to the 3-variable disease activity score in 28
joints (DAS28) [19] using the CRP (DAS28-CRP), or
DAS28 score of <2.6, and the least squares mean change
in components of the ACR core set of disease activity
measures, including the Health Assessment Questionnaire
disability index (HAQ-DI) [20], the 36-item Short Form
(SF-36) Health Survey [21], and the patient’s assessment
of pain and patient’s and physician’s global assessments of
disease activity on 0 to 100-mm visual analog scales.Safety measures
Safety was evaluated by nature, severity, and drug relation
of adverse events (AEs), graded according to National
Cancer Institute Common Toxicity Criteria for Adverse
Events (NCI-CTCAE v3.0) and reported by incidence.
Vital signs, physical examination findings, concomitant
medications, and laboratory and pregnancy test results
were collected every 2 weeks during the study. Incidence
of anti-therapeutic antibodies (ATA) to pateclizumab in
serum was evaluated using a bridging enzyme-linked im-
munosorbent assay (ELISA) on Days 57, 85, and 155 or
early termination.
Pharmacokinetics and immunogenicity assessment
For pharmacokinetic (PK) assessment, serum samples
were obtained at predose Day 1; at 4 hours and at 3 and
6 days after the first dose; predose on Days 15, 29, 57,
and 71; 3 and 14 days after final dose, and during drug
washout for up to 12 weeks. The PK samples were
analyzed using a validated ELISA with a lower limit of
quantification of 100 ng/mL pateclizumab.
For ATA assessment, serum samples were obtained at
predose and multiple postdose time points (Days 57, 85,
155, or early termination) and assessed using a bridging
ELISA [16]. The relative sensitivity of the assay was
estimated to be 50 ng/mL using an anti-pateclizumab
complementarity-determining region (CDR) antibody.
The assay was optimized to minimize interference by RF
and by pateclizumab, and could detect 500 ng/mL of the
anti-CDR antibody in the presence of 50 μg/mL of
pateclizumab.
Pharmacodynamic biomarker assessment
CXCL13 was measured as a pharmacodynamic biomarker,
as identified in the phase 1 study [16,22]. Serum samples
were obtained predose on Day 1 and postdose on Days 15,
29, 57, 71, 74, 85, 113, 141, and 155. A bridging electro-
chemiluminescence assay (ECLA) was validated to quan-
tify CXCL13 in RA serum. Briefly, samples were incubated
with two anti-CXCL13 antibody reagents, one labeled with
biotin. Samples were captured using streptavidin, and
measured using standard immunoassay methods (mini-
mum quantifiable concentration, 20 pg/mL). Patients
without detectable CXCL13 at baseline (n = 14) or with
changes >1,000% of baseline (n = 2) were excluded from
analysis.
Statistical methods
All efficacy analyses were performed using the modified
intent-to-treat (mITT) populations; all safety analyses were
performed using the as-treated population. The primary
efficacy endpoint of change of DAS28(4)-ESR at Day 85
was assessed using an analysis of covariance (ANCOVA)
model with adjustment of concomitant DMARD use,
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cacy endpoints include ACR20, ACR50, and ACR70 re-
sponses at Day 85. Any missing ACR score components
were imputed with the last-observation-carried-forward
(LOCF) method. The P values for comparing treatment
differences in ACR20/50/70 responses were based on the
Cochran-Mantel-Haenszel test with adjustment for stratifi-
cation factors of geographic region and concomitant
DMARD use. The P values were not corrected for multiple
comparisons.
Results
Patient disposition and baseline characteristics
Overall, 214 patients were randomized to receive study
treatment. Of these, 180 received study treatment and
completed the study for efficacy evaluations (mITT). The
34 patients withdrawn prior to the completion of the
study included 13 patients treated with pateclizumab, 11
treated with adalimumab, and 10 treated with placebo.
Reasons for early withdrawal included AE (n = 7), patient




Mean (SD) 50.2 (13.1)
Median 51.0
Range (min, max) 18-75
Age group
<65 yr (%) 72 (84.7%)







American Indian or Alaska Native 1 (1.2%)
Asian (0.0%)
Native Hawaiian or other Pacific Islander (0.0%)
Not available 30 (35.3%)
Region
US and Western Europe 12 (14.1%)
Latin America and Eastern Europe 73 (85.9%)
BMI (kg/m2)
Mean (SD) 27.114 (5.075)
Weight (kg)
Mean (SD) 68.66 (14.88)
ADA, adalimumab; BMI, body mass index; min, max, minimum, maximum; SD, standfollow-up from the pateclizumab cohort (n = 2). An ad-
ditional 11 patients did not meet eligibility criteria. Thus,
of the 214 patients, 170 who received a study treatment
were included in efficacy and safety evaluations.
Randomization achieved treatment groups that were
well balanced for baseline demographic and clinical cha-
racteristics (Table 1). The majority of patients were white
and female; the mean age was 50.1 years. The mean du-
ration of RA disease was 7.2 to 9.3 years, and 84 to 87% of
patients were on methotrexate at randomization.
Primary efficacy endpoint: DAS(4)-ESR at Week 12
Pateclizumab had minimal clinical activity by DAS28(4)-
ESR but this did not reach statistical significance com-
pared to placebo at Week 12. In contrast, adalimumab
demonstrated a robust treatment effect at Week 12. The
mean changes from baseline in DAS28(4)-ESR at Day 85
were −1.89, −2.52, and −1.54 for the pateclizumab, adali-
mumab, and placebo groups, respectively (Table 2). The
differences between adalimumab and the other two
treatment groups in DAS28(4)-ESR mean change fromADA Placebo All patients
(n = 85) (n = 44) (n = 214)
50.6 (13.3) 48.8 (14.0) 50.1 (13.3)
52.0 48.5 51.0
20-73 23-75 18-75
69 (81.2%) 36 (81.8%) 177 (82.7%)
16 (18.8%) 8 (18.2%) 37 (17.3%)
68 (80.0%) 37 (84.1%) 183 (85.5%)
17 (20.0%) 7 (15.9%) 31 (14.5%)
48 (56.5%) 29 (65.9%) 130 (60.7%)
0 (0.0%) 0 (0.0%) 1 (0.5%)
3 (3.5%) 0 (0.0%) 4 (1.9%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
34 (40.0%) 15 (34.1%) 79 (36.9%)
12 (14.1%) 6 (13.6%) 30 (14.0%)
73 (85.9%) 38 (86.4%) 184 (86.0%)
27.309 (4.194) 26.903 (5.547) 27.148 (4.830)
69.52 (12.75) 69.15 (22.61) 69.11 (15.96)
ard deviation.
Table 3 Summary of number and percentage of subjects
with treatment-emergent adverse events
Pateclizumab ADA Placebo
(n = 86) (n = 85) (n = 43)
Any AE 50 (58%) 65 (76%) 31 (72%)
Any SAE 0 (0%) 5 (6%) 1 (2%)
Any AE Grade ≥3 6 (7%) 8 (9%) 3 (7%)
Any drug-related AE 20 (23%) 26 (31%) 10 (23%)
Any AE within 24 hr
of dosing
7 (8%) 27 (32%) 6 (14%)
Any SAE within 24 hr
of dosing
0 (0%) 0 (0%) 0 (0%)
Any drug-related AE
within 24 hr of dosing
4 (5%) 12 (14%) 5 (12%)
Any infection AE 25 (29%) 32 (38%) 19 (44%)
Any infection SAE 0 (0%) 2 (2%) 0 (0%)
Any infection AE Grade 3
or higher
0 (0%) 1 (1%) 0 (0%)
Any AE leading to
discontinuation of study drug
2 (2%) 6 (7%) 1 (2%)
Any death 0 (0%) 0 (0%) 0 (0%)
ADA, adalimumab; AE, adverse event; SAE, serious adverse event.
Table 4 Summary of treatment-emergent adverse events
that occurred ≥3% in any treatment group
Pateclizumab ADA Placebo
(n = 86) (n = 85) (n = 43)
Pharyngitis 7 (8.1%) 7 (8.2%) 4 (9.3%)
Headache 3 (3.5%) 11 (12.9%) 2 (4.7%)
Urinary tract infection 7 (8.1%) 7 (8.2%) 2 (4.7%)
Hypertension 5 (5.8%) 5 (5.9%) 1 (2.3%)
Nasopharyngitis 4 (4.7%) 4 (4.7%) 3 (7.0%)
Anemia 5 (5.8%) 3 (3.5%) 2 (4.7%)
Diarrhea 2 (2.3%) 5 (5.9%) 3 (7.0%)
Alanine aminotransferase
increased
2 (2.3%) 3 (3.5%) 4 (9.3%)
Rheumatoid arthritis 3 (3.5%) 3 (3.5%) 3 (7.0%)
Gastroenteritis 3 (3.5%) 3 (3.5%) 1 (2.3%)
ADA, adalimumab.
Table 2 Primary (DAS28-ESR) and key secondary
endpoints at day 85
Pateclizumab ADA Placebo
(n = 84) (n = 84) (n = 43)
DAS28(4)-ESR score at baseline
Mean (SD) 6.95 (0.89) 6.84 (0.90) 6.80 (0.74)
DAS28(4)-ESR score at day 85
Mean (SD) 5.06 (1.52) 4.31 (1.46) 5.26 (1.44)
DAS28(4)-ESR score change from baseline
Mean (SD) –1.89 (1.38) –2.52 (1.43) –1.54 (1.34)
P value of difference of change scorea
Versus placebo 0.5172 0.0004 –
Versus ADA 0.0003 – –
ACR20 response
n (%) 50 (64.1%) 58 (77.3%) 17 (45.9%)
ACR50 response
n (%) 26 (33.3%) 43 (57.3%) 9 (24.3%)
ACR70 response
n (%) 11 (14.1%) 26 (34.7%) 3 (8.1%)
ACR components, mean (P value vs. placebob)
Swollen joint count –8.9 (0.04) –10.4 (<0.01) –6.1
Tender joint count –13.3 (0.10) –16.3 (<0.01) –9.8
Patient’s global VAS (mm) –28.8 (0.27) –37.0 (<0.01) –24.0
Physician’s global
VAS (mm)
–33.8 (<0.01) –34.1 (<0.01) –23.2
Patient’s pain VAS –26.7 (0.24) –33.5 (<0.01) –21.6
CRP –0.5 (0.08) –1.2 (<0.01) 0.3
ESR –11.9 (0.47) –22.9 (0.04) –14.7
HAQ-DI –0.5 (0.09) –0.8 (<0.01) –0.3
aP value from analysis of covariance; bP value for least squares mean change from
baseline compared with placebo. ACR, American College of Rheumatology; ADA,
adalimumab; CRP, C-reactive protein; DAS28(4), 4-variable, 28-joint disease
activity score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment
Questionnaire disability index; SD, standard deviation; VAS, visual analog scale
(0 to 100).
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the difference between the pateclizumab and placebo
groups was not (P >0.05).
Secondary efficacy endpoints
The ACR50 response was achieved at Day 85 in 26
(33.3%), 43 (57.3%), and 9 (24.3%) patients from the pate-
clizumab, adalimumab, and placebo groups, respectively
(Table 2). The differences between adalimumab and the
two other treatment groups in ACR50 rates were statisti-
cally significant (P <0.01), but the difference between pate-
clizumab and placebo was not (P >0.05). Pateclizumab
failed to reach statistical significance for other key se-
condary efficacy endpoints, including ACR20 and ACR70.Pateclizumab was significantly different from placebo for
two components of the composite ACR score: swollen
joint count (P <0.04) and physician’s global visual analog
scale (VAS) (P <0.01). Adalimumab significantly differed
from placebo in each of the ACR components. In addition,
SF-36 individual and component summary scores also
showed a statistically significant difference between adali-
mumab and pateclizumab but not between pateclizumab
and placebo.
Figure 1 Observed versus population PK model predicted
pateclizumab serum concentration-time profiles. Dose was given
on study days 0, 14, 24, 42, 56, and 70. The empty symbols represent
the observed individual serum concentrations at planned sampling
times. The solid line represents the population PK model (built based
on phase I PK data) predicted median serum concentration-time
profile. The shaded band represents model predicted 90% confidence
interval of the concentration-time profile for the study population.
PK, pharmacokinetic.
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Pateclizumab was generally safe and well tolerated in
this study. No deaths occurred. Six patients had serious
AEs (SAEs): five patients who received adalimumab and
one patient who received placebo. Of the six SAEs, two
(pulmonary tuberculosis (TB) and lymphopenia, both in
the adalimumab group) were judged by the investigator
to be related to the study drug. No patients were with-
drawn from treatment due to an SAE.
AEs in the pateclizumab cohort were comparable in
frequency to the placebo rates (Table 3). In the vastFigure 2 B cell chemoattractant CXCL13 was decreased after treatme
chemoattractant, are presented over time after treatment with adalimumab
treatment with pateclizumab, demonstrating pharmacological engagemen
[12]. Adalimumab also modulated CXCL13 levels to a similar degree. Signifi
*P <0.05 vs. placebo. LTα, lymphotoxin alpha; SEM, standard error of the mmajority of patients, AEs were Grade 1 or 2 in severity;
however, six patients in the pateclizumab group, eight in
the adalimumab group, and three in the placebo group
experienced AEs of Grade 3 or higher. There was one
patient from Peru in the adalimumab-treatment group
who had a negative interferon-gamma release assay
screening result for latent and/or active TB who pre-
sented at randomization on study day 1 with a cough
and subsequently developed an active TB infection.
The most frequent (≥3%) treatment-emergent AEs are
listed in Table 4. From baseline to Week 12, the most
frequently reported AEs were pharyngitis, headache,
urinary tract infection, hypertension, nasopharyngitis
anemia, diarrhea, elevated ALT level, rheumatoid arth-
ritis, and gastroenteritis. No clinically significant changes




Following six biweekly SC doses of 360 mg pateclizumab,
the maximum mean ± standard deviation (SD) observed
serum concentration was 41.1 ± 18.4 μg/mL, and occurred
on Day 74 (3 days following the sixth dose). The observed
steady-state average trough concentration (Ctrough,ss) was
21.3 ± 12.0 μg/mL. The mean trough concentration ratio
of Day 85 (14 days after the last dose) to Day 15 (14 days
after the first dose) was 1.79, indicating a mild exposure
accumulation. The observed PK profile was well aligned
with the profile predicted by a population PK model built
using the PK data from the pateclizumab phase I study
(Figure 1).
Pre- and postdose levels of serum CXCL13 were evalua-
ted as a biomarker for target modulation. The three treat-
ment groups did not significantly differ in mean (± SD)nt with pateclizumab. Mean ± SEM levels of CXCL13, a B cell
, pateclizumab, or placebo. CXCL13 was decreased following
t of the LTα pathway, as observed in the phase 1 trial of pateclizumab
cance was assessed at the efficacy endpoint (Day 85); see Methods.
ean.
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decreased rapidly and significantly in patients treated with
pateclizumab (Figure 2), demonstrating evidence of an on-
target pharmacological effect (P <0.01, pateclizumab vs.
placebo, Day 85). Adalimumab also decreased CXCL13
levels significantly (P <0.01, adalimumab vs. placebo, Day
85), as expected [16]. Serum CXCL13 levels returned to
predose levels for both treatment cohorts during the safety
follow-up. As a comparison, such a treatment pharmaco-
logical effect was not observed in the placebo-treated
group.
Among the 85 patients who were treated with patecli-
zumab, four patients were positive for ATA, and all posi-
tive ATA signals were detected at a single time point on
Day 155, approximately 3 months after the final patecli-
zumab dose.
Discussion
To our knowledge, ALTARA is the first phase 2 study
directly comparing the safety and efficacy of an investi-
gational agent, pateclizumab, with an approved anti-TNF
product for the treatment of DMARD-IR patients on
background DMARDs. Efficacy was directly compared
in a head-to-head study for 3 months of treatment,
which is considered a sufficient duration of treatment
for such comparisons [23,24]. Since adalimumab com-
bined with the standard-of-care methotrexate is one of
the most common therapeutic choices for patients with
RA and an inadequate response to DMARDs, it is an ap-
propriate comparator as an anti-TNF class agent. In
addition, adalimumab is dosed every 2 weeks subcutane-
ously like pateclizumab and the choice of this particular
anti-TNF agent reduced the complexity of maintaining
the blind by reducing the frequency of injections for pa-
tients compared to the use of etanercept. The DAS28-
ESR and ACR scores reported for adalimumab in the
DMARD-IR population in this study are comparable to
historical values for this duration of dosing [25-27].
Pateclizumab had a trend for clinical effects on the signs
and symptoms of rheumatoid arthritis after 3 months of
treatment in patients with active disease and an inadequate
response to DMARDs but the differences from placebo re-
sponses were not statistically significant. Pateclizumab had
an acceptable safety profile, with no SAEs and no increase
in infectious AEs compared to placebo likely related to
its limited immunosuppressant effects. Injection-site AEs
with pateclizumab were uncommon, typically low grade in
severity, and comparable to those with placebo.
The pateclizumab dose regimen evaluated in this study
provided expected and sufficient exposure during the
treatment period as judged by a rapid and sustained de-
crease in serum CXCL13 levels at all times out to 85 days.
The 40 to 50% inhibition of serum CXCL13 levels in the
pateclizumab-treated group in this study confirmed thatthe exposure of 360 mg (approximately 5 mg/kg based on
a median body weight of 72 kg) SC biweekly doses is suffi-
cient to produce maximal downstream pharmacological
effect in blocking the LTα pathway. However, although
such a pharmacodynamic effect was maximized and simi-
lar to the CXCL13 reduction observed in the adalimumab-
treated cohort, pateclizumab treatment was not associated
with significant clinical benefit.
Despite the reports of elevated levels of LTα and LTβ
expression in the synovium of RA patients [5,6,28], as well
as the presence of lymphoid aggregates, targeting of the
LT pathway with pateclizumab did not have insignificant
treatment effects compared to adalimumab. Baminercept,
an LTβR fusion protein that only blocks LTα1β2-LTβR
interaction, was evaluated in two clinical trials and found
not to be efficacious for the treatment of the signs and
symptoms of RA. In a 14-week, dose-ranging phase 2b
trial in DMARD-IR patients (N = 391) [29] and in a
14-week, dose-ranging phase 2b trial in TNF-IR patients
(N = 114) [9], baminercept did not have significant treat-
ment effects as assessed by ACR50 response rates. In this
second study, baminercept did reduce CXCL13 levels by
approximately 50% [9], which is similar to our phar-
macodynamic results with pateclizumab in DMARD-IR
patients.Conclusions
Our findings suggest that targeting lymphotoxin signal-
ing, LTα3-TNFR interactions and LTα1β2-LTβR interac-
tions, with pateclizumab on background DMARDs is
insufficient to produce a significant reduction in the in-
flammatory process in RA or to provide superior efficacy
over adalimumab, an anti-TNF agent that is commonly
used for DMARD-IR RA patients.
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